US20050255172A1 - Hydrogen peroxide-based skin disinfectant - Google Patents

Hydrogen peroxide-based skin disinfectant Download PDF

Info

Publication number
US20050255172A1
US20050255172A1 US11128223 US12822305A US2005255172A1 US 20050255172 A1 US20050255172 A1 US 20050255172A1 US 11128223 US11128223 US 11128223 US 12822305 A US12822305 A US 12822305A US 2005255172 A1 US2005255172 A1 US 2005255172A1
Authority
US
Grant status
Application
Patent type
Prior art keywords
solution
acid
hydrogen
peroxide
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11128223
Inventor
Navid Omidbakhsh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Virox Technologies Inc
Original Assignee
Virox Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/40Peroxides
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES, AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N59/00Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/19Cosmetics or similar toilet preparations characterised by the composition containing inorganic ingredients
    • A61K8/22Peroxides; Oxygen; Ozone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/30Cosmetics or similar toilet preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toilet preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36Carboxylic acids; Salts or anhydrides thereof
    • A61K8/368Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms or aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/30Cosmetics or similar toilet preparations characterised by the composition containing organic compounds
    • A61K8/40Cosmetics or similar toilet preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/30Cosmetics or similar toilet preparations characterised by the composition containing organic compounds
    • A61K8/40Cosmetics or similar toilet preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A61K8/442Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof substituted by amido group(s)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/30Cosmetics or similar toilet preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toilet preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494Cosmetics or similar toilet preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4946Imidazoles or their condensed derivatives, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/30Cosmetics or similar toilet preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toilet preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973Cosmetics or similar toilet preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/30Cosmetics or similar toilet preparations characterised by the composition containing organic compounds
    • A61K8/55Phosphorus compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILET PREPARATIONS
    • A61Q17/00Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/005Antimicrobial preparations
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y02A50/46Medical treatment of waterborne diseases characterized by the agent
    • Y02A50/468The waterborne disease being caused by a bacteria
    • Y02A50/473The waterborne disease being caused by a bacteria the bacteria being Escherichia coli, i.e. E. coli Infection

Abstract

A skin disinfectant in ready-to-use concentrated liquid or dry powdered form. Ready-to-use liquid forms have a pH of from about 2 to about 6 and include: (a) hydrogen peroxide in a concentration of from about 0.01 to about 4% w/w of the solution; (b) at least one surfactant chosen from imidazoline derivatives, alkyl betaines, alkyl amidopropyl betaine amides, alkyl amidopropyl betaines, alkylsulfo betaines, amine oxides and derivatives thereof in a concentration of from about 0.01 to about 15% w/w of the solution; (c) at least one hydrogen peroxide stabilizer in a concentration of from about 0.01 to about 4% w/w of the solution; (d) at least one member chosen from cyclic carboxylic acids and salts thereof in a concentration of from about 0.01 to about 4% w/w of the solution; and (e) at least one skin conditioning agent in a concentration of from about 0.01 to about 10% w/w of the solution.

Description

  • [0001]
    This application claims the benefit of U.S. provisional application No. 60/570,807, filed May 14, 2004 under 35 U.S.C. 119 (e).
  • FIELD OF THE INVENTION
  • [0002]
    The present invention relates to disinfecting solutions or formulations for use on skin containing hydrogen peroxide.
  • BACKGROUND OF THE INVENTION
  • [0003]
    Infection control is a major concern for health care professionals. Viruses and bacteria on contaminated hands are easily spread among people in health care facilities such as hospitals. Of course, the risk of infection is also present in public places other than hospitals, such as in gyms, washrooms, restaurants, and schools.
  • [0004]
    Washing hands with detergents or soaps is a way to reduce the risk of infection. However, in certain environments, such as hospitals, the level of disinfection required cannot be achieved by most common products. Consequently, hand disinfectants have been developed to achieve higher levels of disinfection where the need exists. These types of products generally contain alcohols, iodinesaodophors, chlorhexidine gluconate (CHG), phenolic compounds, quaternary ammonium compounds or combinations thereof.
  • [0005]
    A problem with existing products is that they often sacrifice disinfectant activity for the sake of skin mildness or vice versa. For example, while raising the concentration of the active ingredient may lead to a higher level of disinfection, such higher concentration frequently leads to increased skin irritation.
  • [0006]
    As well, many common disinfecting ingredients have inherent disadvantages. For example, while alcohols are effective in providing rapid rates of disinfection, they are flammable and therefore give rise to safety risks in use and storage. As defatting agents, they can cause dry, chapped or cracked skin on repeated use. Furthermore, their anti-microbial activity is dependent on concentration and tends to drop dramatically when used on wet hands resulting in insufficient germ kill. To overcome some of these disadvantages, it is known to include additional ingredients such as emollients, humectants, and surfactants. For example, U.S. Pat. No. 6,617,294 to Narula et al. issued Sep. 9, 2003 discloses a waterless disinfecting hand cleanser made of a combination of 60 to 90% w/w of an alcohol, silicone based materials, and humectants.
  • [0007]
    Parachlorometaxylenol (PCMX) and triclosan are common phenolic compounds used in antiseptic hand wash solutions. See, for example, European patent 505,935 B1, assigned to Becton, Dickinson and Company and granted on Feb. 4, 1998, which discloses an anti-microbial skin formulation containing PCMX, a block copolymer, and a lauryl sulfosuccinate. Although PCMX and triclosan have lower toxicity than other phenols, and are rather mild to the skin, their germicidal activity is low and depends on the formulation ingredients.
  • [0008]
    Iodine and iodophors have been used in antiseptic hand wash formulations for a long time. Their germicidal activities are low and reduced in the presence of organic matter. Furthermore, these ingredients are toxic and can irritate and stain skin.
  • [0009]
    Chlorhexidine gluconate (CHG) is used as a skin cleanser, pre-surgical scrub, germicidal hand rinse, and wound cleaner. It is less effective against gram-negative bacteria as compared to gram-positive bacteria and exhibits relatively low germicidal activity.
  • [0010]
    Hydrogen peroxide is a broad-spectrum germicide effective against bacteria, yeast, fungi, viruses and spores. It is non-toxic and its breakdown products, oxygen and water, are innocuous thus making it safe to the environment. At low concentrations (e.g. 3% w/w), it is non-irritating to skin, but exhibits low germicidal activity. For example, a solution containing 3% w/w hydrogen peroxide takes 20 minutes to achieve a greater than 6 log reduction in Staphylococcus aureus, which is too long for many applications. Increasing the concentration of hydrogen peroxide will increase the rate of disinfection. For example, a 25% w/w aqueous solution of hydrogen peroxide requires only 20 seconds to achieve a greater than 6 log reduction in Staphylococcus aureus. However, the solution is corrosive at this concentration and requires special handling procedures.
  • [0011]
    While skin disinfecting formulations exist, there is still a need for new formulations that are both safe and capable of achieving an effective rate of disinfection at realistic contact times. The present invention is intended to meet this need.
  • SUMMARY OF THE INVENTION
  • [0012]
    The invention provides, in accordance with a first aspect, an aqueous skin disinfecting solution having a pH of from about 2 to about 6, about 2.5 to about 5, or about 3 to about 5, and comprising:
      • (a) hydrogen peroxide in a concentration of from about 0.01 to about 4% w/w, from about 0.25 to about 3% w/w, or from about 1 to about 3% w/w, of the solution;
      • (b) at least one surfactant chosen from imidazoline derivatives, alkyl betaines, alkyl amidopropyl betaines, alkyl amidopropyl betaine amides, alkylsulfobetaines, amine oxides, and derivatives thereof, in a concentration of from about 0.01 to about 15% w/w, from about 0.3 to about 10% w/w, or from about 1 to 5% w/w, of the solution;
      • (c) at least one hydrogen peroxide stabilizer in a concentration of from about 0.01 to about 4 % w/w, from about 0.01 to about 3% w/w, from about 0.01 to about 2% w/w, or from about 0.1 to 0.5% w/w, of the solution;
      • (d) at least one member chosen from cyclic carboxylic acids and salts thereof in a concentration of from about 0.01 to about 4% w/w, or from about 0.05 to about 1% w/w, of the solution;
      • (e) at least one skin conditioning agent in a concentration of from about 0.01 to about 10% w/w, or from about 0.5 to about 4% w/w, of the solution.
  • [0018]
    Preferred imidazoline derivatives are alkylamphocarboxylates and alkyliminocarboxylates.
  • [0019]
    The hydrogen peroxide stabilizer can be chosen from phosphoric acid, phosphonic acids having 1 to 5 phosphonic acid groups, e.g. 1-hydroxyethylidene-1,1,-diphosphonic acid, amino tri(methylene phosphonic acid), diethylenetriaminepenta(methylene phosphonic acid), 2-hydroxy ethylimino bis(methylene phosphonic acid), and ethylene diamine tetra(methylene phosphonic acid). They can also be chosen from sodium tripolyphosphate, ethylenediaminetetraacetic acid (EDTA), diethylenetriaminepentaacetic acid (DTPA), N-(hydroxyethyl)-ethylenediaminetriacetic acid (HEDTA), nitrilotriacetic acid (NTA), 2-hydroxyethyliminodiacetic acid (HEIDA), benzoic acid, aminobenzoic acid, citric acid, iminodisuccinic acid, polyaspartic acid, and salts thereof.
  • [0020]
    The cyclic carboxylic acid can be chosen from furan carboxylic acid (e.g. 2-furan carboxylic acid), benzoic acid and salicylic acid.
  • [0021]
    The skin-conditioning agent can be chosen from glycerides, sorbitol, castor oil, allantoin, cationic polymers, lanolin and its derivatives and cetyl alcohol.
  • [0022]
    The solution can further comprise at least one buffer, in a concentration of from about 0.01 to about 5% w/w of the solution, chosen from citric acid, lactic acid, glycolic acid, phosphoric acid, malic acid, succinic acid and tartaric acid.
  • [0023]
    In other embodiments, the solution can comprise at least one optional hydrogen peroxide compatible surfactant in a concentration of from about 0.01 to about 10% w/w of the solution. Exemplary hydrogen peroxide compatible surfactants are alkyl sulfate, alkyl ether sulfates, alkyl benzene sulfonic acids, alkyl sulfonic acids, alkyl diphenyl oxide sulfonic acids, naphthalene sulfonic acids, alkyl or alkenyl esters or diesters of sulfosuccinic acids, and salts thereof, alcohol ethoxylates, alkyl phenol ethoxylates, fatty acid esters, and alkylpolyglucosides.
  • [0024]
    As well, the solution can comprise at least one C1 to C8 alcohol in a concentration of from about 0.01 to about 10% w/w of solution, which may be chosen from benzyl alcohol, ethanol, n-butanol, isopropanol and glycols.
  • [0025]
    The solution can further comprise at least one member chosen from monocarboxylic acids, polycarboxylic acids, and mixtures thereof in a concentration of from about 0.01 to about 3% w/w of the solution. These ingredients have known pH buffering, stabilizing and cleaning properties. Preferred monocarboxylic acids are glycolic acid and acetic acid. A preferred polycarboxylic acid is citric acid.
  • [0026]
    To improve the rheological properties and attractiveness of the solution, the solution can further comprise at least one thickening agent compatible with hydrogen peroxide (e.g. polyacrylic acid polymers, polysaccharides, and cellulose-based polymers in a concentration of from about 0.01 to about 5% w/w of the solution, and at least one member chosen from dyes and fragrances (as are known in the art) in a concentration of from about 0.001 to about 0.5% w/w of the solution.
  • [0027]
    The balance of the solution consists of deionized water, preferably with a conductivity of less than 20 micro zimens. It will be appreciated that the lower the deionized water conductivity, the longer the shelf life.
  • [0028]
    In accordance with a second aspect of the invention, the solution may be in concentrated liquid form for dilution by the end user. Similarly, in accordance with a third aspect, the invention may take the form of a dry powdered formulation, which can be dissolved in water to form a solution according to the first aspect.
  • DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
  • [0029]
    When used herein, the expression “consisting essentially of” shall mean—including the listed ingredients and such additional ingredients as would not materially affect the basic and novel properties of the invention—. The basic and novel properties are the disinfecting properties of the invention and the suitability of the invention for use on skin.
  • [0030]
    The term “comprising” shall mean—including but not limited to—.
  • [0031]
    A “skin-conditioning agent” is any ingredient or compound, which is used to make the solution suitable for use on skin and includes moisturizers, emollients and humectants.
  • [0032]
    Certain ingredients used in the present inventive solution can serve more than one function. For example, phosphoric acid and citric acid are both hydrogen peroxide stabilizers and buffers. Similarly, benzoic acid is also a hydrogen peroxide stabilizer and a cyclic carboxylic acid, which contributes to disinfecting activity.
  • [0033]
    The inventive solution is able to provide adequate levels of disinfection while not irritating skin. The solution is non-irritating due to the low levels of hydrogen peroxide, mild surfactant package and low concentrations of other mild additives employed. The solution has broad-spectrum activity, the degree of which is unexpected given the germicidal activity of the individual ingredients. A synergy exists amongst the ingredients of the present inventive solution such that an effective disinfectant is provided that is suitable for use on skin.
  • [0034]
    Commercial solutions having hydrogen peroxide concentrations of from about 10 to about 50% w/w, (e.g. about 35% w/w or about 50% w/w), may be used to prepare solutions according to the invention. Such commercial solutions typically contain additional stabilizers and additives as are known in the art and are available from manufacturers such as FMC and Degussa AG.
  • [0035]
    As mentioned above, the invention may be in the form of a concentrated liquid for dilution by the end user. Alternatively, it may be in the form of a dry formulation for dissolution in water. In such dry formulation, the hydrogen peroxide may be supplied by persalt compounds, of which sodium percarbonate and sodium perborate in its monohydrate and tetrahydrate forms are preferred. Since sodium percarbonate contains about 20% hydrogen peroxide by weight, and sodium perborate monohydrate and sodium perborate tetrahydrate contain about 30% and about 20% respectively by weight, proper allowance must be made when blending the dry mixture of components to achieve the desired levels of hydrogen peroxide upon dissolution in water.
  • [0036]
    As noted above, certain surfactants are essential to the present invention, including, imidazoline derivatives (e.g. alkylamphoacetates, alkylamphopropionates, and alkyliminopropionates), alkylbetaines, alkylamidopropylbetaines, alkyl amidopropyl betaine amides, alkylsulfobetaines, amine oxides and derivatives and mixtures thereof. These surfactants are available from a variety of sources, including Rhodia, which manufactures and sells imidazoline derivatives in association with the trademark MIRANOL and an alkylamidopropylbetaine in association with the trademark MIRATAINE. Seppic manufactures and sells surfactants useful in the present invention in association with the trademark MONTALINE. Cognis manufactures and sells useful surfactants in association with the trademark DEHYTON. Stepan manufactures and sells amine oxides in association with the trademark AMMONYX. Lonza manufactures and sells imidazoline derivative and alky betaines in association with the trademarks AMPHOTERGE and LONZAINE.
  • [0037]
    Amine oxides useful in this invention are R1R2R3NO wherein each of R1, R2, and R3 is independently a saturated, substituted or unsubstituted linear or branched alkyl group having from 1 to 28 carbon atoms.
  • [0038]
    Preferred imidazoline derivatives are alkylamphocarboxylates and alkyliminocarboxylates having the following structures:
    Figure US20050255172A1-20051117-C00001

    wherein R is a saturated, substituted or unsubstituted linear or branched alkyl group having from 1 to 24 carbon atoms. Preferably, R is a linear alkyl chain having from 8 to 16 carbon atoms and R1 to R5 are saturated, linear alkyl groups having from 1 to 3 carbon atoms.
  • [0039]
    Alkyl amidopropyl betaine amides useful in this invention have a saturated, substituted or unsubstituted linear or branched alkyl group having from 1 to 24 carbon atoms. The alkyl group is preferably a linear chain having from 6 to 16 carbon atoms.
  • [0040]
    Alkyl amidosulfobetaines have the following structure:
    Figure US20050255172A1-20051117-C00002

    wherein R is a saturated, substituted or unsubstituted linear or branched alkyl group having from 1 to 24 carbon atoms. The alkyl group is preferably a linear alkyl chain having 8 to 16 carbon atoms.
  • [0041]
    Preferred hydrogen peroxide stabilizers are available from a number of manufacturers including Rhodia under the trademark BRIQUEST, and Solutia under the trademark DEQUEST.
  • [0042]
    The invention will be better understood with reference to the following examples. In such examples, the following ingredients were used.
  • [0000]
    Hydrogen Peroxide
  • [0043]
    The hydrogen peroxide used in all the examples is a 50% w/w technical grade commercial solution sold by Degussa AG.
  • [0000]
    Hydrogen Peroxide Stabilizer
  • [0000]
      • BRIQUEST ADPA 60 AW: 1-hydroxyethylidene-1,1,-diphosphonic acid, sold by Rhodia as a 60% w/w solution.
      • BRIQUEST 301-50A: nitrilotris (methylenephosphonic acid), sold by Rhodia as a 50% w/w solution.
      • VERSENE 100: tetrasodium ethylenediaminetetraacetate, sold by Dow Chemicals as a 37% w/w solution.
      • VERSENE NTA 148: trisodium nitrilotriacetate, sold by Dow Chemicals as a 38% w/w solution.
      • VERSENE HEIDA: disodium salt of 2-hydroxyethyliminodiacetic acid, sold by Dow Chemicals as a 41% w/w solution.
      • BAYPURE CX: Sodium salt of iminodisuccinic acid, sold by Lanxess as a 100% w/w powder.
      • BAYPURE DS: Sodium salt of polyaspartic acid, sold by Lanxess as a 100% w/w powder.
        Surfactants
      • DEHYTON MC: sodium cocoamphoacetate, sold by Cognis as a 40% w/w solution.
      • AMPHOTERGE K-2: disodium cocamphopropionate, sold by Lonza as a 40% w/w solution.
      • AMPHOSOL CG: cocamidopropyl betaine, sold by Stepan as a 30% w/w solution.
      • MIRANOL C2M CONC NP: cocampho diacetate, sold by Rhodia as a 30% w/w solution.
      • MONTALINE C40: cocamidopropyl betaineamide monoethanolamine chloride (quaternized coconut oil), sold by Seppic as a 38% w/w solution.
      • LONZAINE 16SP: cetyl dimethyl betaine, sold by Lonza as a 35% w/w solution.
      • MIRATAINE CBS: Cocamido propyl hydroxy sultaine, sold by Rhodia as a 43.5% w/w solution.
      • AMMONYX LO: lauramine oxide, sold by Stepan as a 30% w/w solution.
      • AMMONYX CDO: cocamidopropylamine oxide, sold by Stepan as a 30% w/w solution.
        Skin Conditioning Agents
      • POLYQUATERNIUM-11: cationic copolymer of vinyl-pyrrolidone and dimethylaminoethylmethacrylate quaternized with diethyl sulfate, sold by ISP as a 20% w/w solution.
      • POLYQUATERNIUM-7: cationic copolymer of dimethyldiallylammonium chloride and acrylamide, sold by Mcintyre Group Ltd. as a 9% w/w solution.
      • MERGITAL EL33: polyethylene glycol castor oil, sold by Cognis as a 9% w/w solution.
      • Glycerin
        Additional Optional Surfactants
      • STEPAN MILD SL3 BA: disodium lauryl ether sulfosuccinate ethoxylated to 3 moles ethylene oxide (EO), sold by Stepan as a 32% w/w solution.
      • SURFYNOL 104PG-50: 2,4,7,9 tetramethyl-5 decyne-4,7 diol, sold by Air Products as a 50% w/w solution.
      • ETHAL OA-23: Oleyl (C18) alcohol ethoxylate, 23 moles of EO/mole of alcohol, sold by Ethox Company as a 70% w/w solution.
      • TERGITOL 15-S-7: C11-C14 secondary alcohol ethoxylate, 7 moles of EO/mole of alcohol, sold by Union Carbide as a 100% w/w liquid.
      • TERGITOL 15-S-5: C11-C14 secondary alcohol ethoxylate, 5 moles of EO/mole of alcohol, sold by Union Carbide as a 100% w/w liquid.
        Thickening Agents
      • CARBOPOL 676: acrylic polymer, sold by Noveon Company as a 100% w/w powder.
      • NATRASOL 250 HR: Hydroxyethylcellulose, sold by Hercules as a 100% w/w powder.
      • KLUCELL HF: Hydroxypropylcellulose, sold by Hercules as a 100% w/w powder.
    EXAMPLES
  • [0072]
    SOLUTION 1
    INGREDIENTS % w/w Actual concentration % w/w
    deionized water Up to 100 Up to 100
    BRIQUEST ADPA 60 AW 0.6 0.36
    salicylic acid 0.01 0.01
    Glycerin 3 3
    DEHYTON MC 3 1.2
    MONTALINE C40 1 0.38
    AMMONYX CDO 3 0.9
    benzoic acid 0.2 0.2
    POLYQUATERNIUM-11 0.8 0.16
    MERGITAL EL33 1 0.09
    hydrogen peroxide 4 2
    pH 4
  • [0073]
    Solution 1 is a hand disinfectant, which, at a 55% dilution achieved a greater than 4 log 10 reduction in Staphylococcus aureus and E. coli at 30 second contact time using European suspension test method EN.12054. The solution was also tested against these organisms in vivo using European fingerpad test method EN.1499.
  • [0074]
    Test method EN.1499 involves preparing 2 liters of a contamination fluid containing from 2×108-2×109 test organisms. The test organisms are prepared in Tryptone Soy Broth TSB and pooled overnight. Hands are washed with soft soap and water to remove any soil and then dried. The hands are then immersed up to the mid-metacarpals in the contamination fluid with the fingers spread apart. Immersion is for 5 seconds. The hands are then air dried for 3 minutes while moving the hands to avoid droplet formation.
  • [0075]
    Immediately after drying, the hands are sampled to establish a baseline or “pre-value” count of test organisms. This is achieved by rubbing the fingertips (including the thumb) against the base of a petri dish containing 10 ml TSB on a neutralization bath (designed to neutralize the activity of the test product) for 60 seconds. A separate petri dish is used for each hand. A series of 10-fold dilutions of the neutralization bath is prepared and each dilution is plated on a well-dried Tryptone Soy Agar (TSA) plate and incubated at 37° C. for 18-24 hours. The number of surviving colony forming units of microorganisms on each plate is then counted and the value is expressed in terms of log 10.
  • [0076]
    The product to be tested is poured into cupped hands which had been dipped in the contaminated fluid in the same manner described above. The product is rubbed vigorously into the skin up to the wrists for 60 seconds to ensure total coverage of the hands. The fingers are then rinsed under running tap water for 15 seconds and excess water is shaken off.
  • [0077]
    The hands are then sampled individually to establish a post treatment or “post-value” count of test organisms. This is performed using exactly the same method as that used to establish the pre-value count. That is, the fingertips (including the thumb) are rubbed against the base of a petri dish (one for each hand) containing 10 ml TSB in a neutralization bath for 60 seconds. A series of 10-fold dilutions of the neutralization bath is prepared and each dilution is plated on a well-dried TSA plate and incubated at 37° C. for 18-24 hours. The number of surviving colony forming units of microorganisms on each plate is then counted and the value is expressed in terms of log 10.
  • [0078]
    5 ml of a soft soap which does not have any antimicrobial active ingredients, is used as a control and tested in the above same manner.
  • [0079]
    After recording the number of colony forming units for each dilution of the sample neutralization fluid, the number of colony forming units per ml is calculated and expressed in terms of log 10. For both test and control products, the mean log counts from left and right hands are used to determine the pre- and post-values. The difference between the mean pre-value and the mean post-value counts is then calculated and a log reduction factor for the test product and the control product is calculated using the WILCOXON's ranked pairs test. For a product to conform to standard EN.1499, the log 10 reductions calculated for the test product must be significantly better (pr=0.01) than those calculated for the control product.
  • [0080]
    Test method EN.12054 is a suspension test method, which entails pipetting 9.0 ml of the test solution into a 25 ml capacity sterile container. 1 ml of a bacterial test suspension is then added and mixed with the test solution. The container is then placed in a water bath at 20±1° C. for a defined contact time. Just before conclusion of the defined contact time, the solution is mixed and 1.0 ml is transferred into a tube containing 8 ml of a neutralizer and 1 ml of water. The solution is then mixed again and the tube is placed in a water bath at 20±1° C. After a neutralization time of 5 minutes ±10 seconds, a series of ten-fold dilutions of the neutralized mixture is prepared. A sample of 1 ml of the mixture and 1 ml of its 10−1 dilution is taken in duplicate and incubated by using the pour plate or spread plate technique. In the pour plate technique, each 1 ml sample of the mixture is pipetted onto a separate petri dish containing 12 to 15 ml of melted TSA cooled to 45±1° C. In the spread plate technique, each 1 ml sample of the mixture is spread on an appropriate number of oven-dried plates containing TSA.
  • [0081]
    The plates are then incubated at 36±1° C. for 24 hours after which the number of colony forming units for each plate is determined. The plates are incubated for another 24 hours and the colony forming units are recounted. The highest count value for each plate is used to determine the effectiveness of the test solution. Results are expressed in terms of log 10. A 3-log reduction is the criteria for passing this test method.
    SOLUTION 2
    INGREDIENTS % w/w Actual concentration % w/w
    deionized water Up to 100 Up to 100
    citric acid Up to Up to pH = 4
    pH = 4
    Glycerin 1 1
    BRIQUEST ADPA 60 AW 0.6 0.36
    STEPAN MILD SL3 BA 4 1.28
    AMMONYX LO 0.7 0.21
    POLYQUATERNIUM-11 0.8 0.16
    hydrogen peroxide 6 3
  • [0082]
    Solution 2 does not contain any cyclic carboxylic acids and is therefore not in accordance with the present invention. This solution (at 55% dilution) failed the in vitro European suspension test method EN.12054 using a contact time of 1 minute.
    SOLUTION 3
    INGREDIENTS % w/w Actual concentration % w/w
    deionized water Up to 100 Up to 100
    citric acid 0.1 0.1
    glycerin 1 1
    BRIQUEST ADPA 60 AW 0.6 0.36
    STEPAN MILD SL3 BA 4 1.28
    salicylic acid 0.17 0.17
    POLYQUATERNIUM-11 0.8 0.16
    hydrogen peroxide 6 3
    KOH Up to Up to pH = 4.0
    pH = 4.0
  • [0083]
    Solution 3 does not contain any surfactants which are essential to the present invention and is therefore not in accordance with the present invention. This solution (at 55% dilution) failed the in vitro European suspension test method EN. 12054 using a contact time of 1 minute.
  • [0084]
    What follows are additional exemplary solutions according to the present invention.
    SOLUTION
    4 5 6 7 8
    INGREDIENTS % w/w % w/w % w/w % w/w % w/w
    deionized water Qs to 100
    hydrogen peroxide 3 4 3 3 3
    1.5 2 1.5 1.5 1.5
    benzoic acid 0.17 0.17 0.15 0.17 0.17
    0.17 0.17 0.15 0.17 0.17
    BRIQUEST ADPA 60 AW 0.5 0.5 0.5 0.5 0.5
    0.3 0.3 0.3 0.3 0.3
    lactic acid 0.5
    0.4
    DEHYTON MC 0.5 0.5 0.5 0.5 0.5
    0.2 0.2 0.2 0.2 0.2
    AMMONYX CDO 0.5 0.2 0.5 0.5
    0.15 0.06 0.15 0.15
    MIRANOL C2M CONC NP 0.5 0.7 0.7
    0.15 0.21 0.21
    MERGITAL EL33 2.5 1.0
    0.225 0.09
    sorbitol 2.0
    2.0
    glycerin 3.0 2.5 4.0
    3.0 2.5 4.0
    benzyl alcohol 2.5
    2.5
    isopropyl alcohol 2.0
    1.4
    NaOH (50%) To To To To To
    pH = 3.0 pH = 5.5 pH = 5.0 pH = 5.0 pH = 4.0
    SOLUTION
    9 10 11 12 13
    INGREDIENTS % w/w % w/w % w/w % w/w % w/w
    deionized water Qs to 100
    hydrogen peroxide 3 4 3 4 3
    1.5 2 1.5 2 1.5
    benzoic acid 0.17 0.17 0.17
    0.17 0.17 0.17
    salicylic acid 0.15 0.02
    0.15 0.02
    2-furan carboxylic acid 0.5
    0.5
    BRIQUEST 301-50A 0.5 0.5 0.5
    0.25 0.25 0.25
    VERSENE NTA 148 0.5
    0.5
    VERSENE 100 0.4
    0.4
    MIRANOL C2M CONC NP 25 40 7 10
    7.5 12 2.1 3
    ETHAL OA-23 0.05 0.05 0.1 0.07
    0.04 0.04 0.07 0.05
    AMMONYX CDO 20 10 0.5
    6 3 0.15
    NATRASOL 250 HR 0.5
    0.5
    glycerin 5.0
    5.0
    benzyl alcohol 2.0
    2.0
    isopropyl alcohol 2.0
    1.4
    NaOH (50%) To To To To To
    pH = 2.5 pH = 3.5 pH = 5.0 pH = 6.0 pH = 5.0
    SOLUTION
    14 15 16 17 18
    INGREDIENTS % w/w % w/w % w/w % w/w % w/w
    deionized water Qs to 100
    hydrogen peroxide 3 4 3 4 3
    1.5 2 1.5 2 1.5
    benzoic acid 0.17 0.17 0.17
    0.17 0.17 0.17
    salicylic acid 0.15 0.02
    0.15 0.02
    2-furan carboxylic acid 0.5
    0.5
    BRIQUEST 301-50A 0.5 0.5 0.5 0.5 0.5
    0.25 0.25 0.25 0.25 0.25
    citric acid 1.0
    1.0
    AMPHOSOL CG 0.3 0.5 0.7 0.7
    0.09 0.15 0.21 0.21
    SURFYNOL 104PG-50 0.1 0.05 0.05 0.1 0.07
    0.05 0.03 0.03 0.05 0.04
    AMMONYX LO 6.0 0.5 0.5
    1.8 0.15 0.15
    CARBOPOL 676 0.3
    0.3
    sorbitol 4.0
    4.0
    benzyl alcohol 2.0
    2.0
    isopropyl alcohol 2.0
    1.4
    NaOH (50%) To To To To To
    pH = 2.5 pH = 3.0 pH = 5.0 pH = 6.0 pH = 5.0
    SOLUTION
    19 20 21 22 23
    INGREDIENTS % w/w % w/w % w/w % w/w % w/w
    deionized water Qs to 100
    hydrogen peroxide 3 4 3 4 3
    1.5 2 1.5 2 1.5
    benzoic acid 0.2 0.15 0.17
    0.2 0.15 0.17
    salicylic acid 0.15 0.04
    0.15 0.04
    2-furan carboxylic acid 0.3
    0.3
    BRIQUEST 301-50A 0.4 0.5 0.5 0.5 0.5
    0.2 0.25 0.25 0.25 0.25
    citric acid 1.0
    1.0
    AMPHOTERGE K-2 0.7 0.8 0.8 1.0 0.5
    0.28 0.32 0.32 0.4 0.2
    AMMONYX LO 0.2 0.5 0.5
    0.06 0.15 0.15
    KLUCEL HF 0.5
    0.5
    allantoin 0.05
    0.05
    glycerin 10 4.0 5.0 2.0 3.0
    10 4.0 5.0 2.0 3.0
    benzyl alcohol 2.0
    2.0
    isopropyl alcohol 2.0
    1.4
    NaOH (50%) To To To To To
    pH = 2.5 pH = 3.5 pH = 5.0 pH = 6.0 pH = 5.0
    SOLUTION
    24 25 26 27 28 29
    INGREDIENTS % w/w % w/w % w/w % w/w % w/w % w/w
    deionized water Qs to 100
    hydrogen peroxide 6 8 8 8 8 1.0
    3 4 4 4 4 0.5
    benzoic acid 0.2 0.1 0 0.1 0.1 0.1
    0.2 0.1 0 0.1 0.1 0.1
    salicylic acid 0.1 0.2 0.1 0.1 0.1
    0.1 0.2 0.1 0.1 0.1
    BRIQUEST ADPA 60AW 3.0 4.0 4.0 4.0 2.4
    0.18 2.4 2.4 2.4 2.4
    VERSENA HEIDA 4.0 2.5
    1.6 1.0
    citric acid 1.0 1.0 1.0 1.0 1.0 1.0
    1.0 1.0 1.0 1.0 1.0 1.0
    TERGITOL 15-S-7 5.0 7.0 7.0 7.0 7.0 7.0
    5.0 7.0 7.0 7.0 7.0 7.0
    TERGITOL 15-S-5 2.0 3.0 3.0 3.0 3.0 3.0
    2.0 3.0 3.0 3.0 3.0 3.0
    ETHAL OA-23 0.2 0.1 3.0 1.2 1.2 1.2
    0.14 0.07 2.1 0.84 0.84 0.84
    glycolic acid 2.0 1.0 1.0 1.0 1.0 1.0
    1.2 0.6 0.6 0.6 0.6 0.6
    phosphoric acid 1.0 1.0 1.0 1.0 1.0
    0.75 0.75 0.75 0.75 0.75
    AMMONYX LO 3.0 2.0 2.0 14 5.0 5.0
    0.9 0.6 0.6 4.2 1.5 1.5
    AMPHOSOL CG 5.0 5.0 5.0
    1.5 1.5 1.5
    MONTALINE C40 4.0 10 4.0 4.0
    1.6 4.0 1.6 1.6
    MIRANOL C2M CONC NP 7.0 5.0 5.0
    2.1 1.5 1.5
    glycerin 3.0 1.0 2.0 7.0 8.0 4.0
    3.0 1.0 2.0 7.0 8.0 4.0
    propylene glycol 0 0 0 1.0 1.0 1.0
    0 0 0 1.0 1.0 1.0
    NaOH (50%) To pH = 4.0
    SOLUTION
    30 31
    INGREDIENTS % w/w % w/w
    deionized water Qs to 100
    hydrogen peroxide 3 4
    1.5 2.0
    benzoic acid 0.2
    0.2
    salicylic acid 0.15
    0.15
    BRIQUEST 301-50A 0.4 0.5
    0.2 0.25
    citric acid 1.0
    1.0
    LONZAINE 16SP 5.0
    1.8
    MIRATAINE CBS 3.0
    1.3
    AMMONYX LO 1.0 0.3
    0.3 0.1
    CARBOPOL 676 0.5
    0.5
    allantoin 0.05
    0.05
    glycerin 4.0
    4.0
    sorbitol 5.0
    5.0
    NAOH (50% Up to pH = 4 Up to pH = 5
    pH 4 5
    SOLUTION
    32 33 34 35
    INGREDIENTS % w/w % w/w % w/w % wlw
    deionized water Qs to 100
    hydrogen peroxide 6 8 6 8
    3 4 3 4
    benzoic acid 0.17 0.1 0.17 0.1
    0.17 0.1 0.17 0.1
    salicylic acid 0.17 0.1 0.17 0.1
    0.17 0.1 0.17 0.1
    BRIQUEST ADPA 60AW 0.35 4.0
    0.21 2.4
    BAYPURE CX 0.5
    0.5
    BAYPURE DS 0.4
    0.4
    citric acid 0.1 1.0 0.1 1.0
    0.1 1.0 0.1 1.0
    AMMONYX LO 3.0 2.0 3.0 2.0
    0.9 0.6 0.9 0.6
    AMPHOSOL CG 6.0 6.0
    1.8 1.8
    MONTALINE C40 4.0 4.0
    1.6 1.6
    POLYQUATERNIUM-7 0.8 0.8
    0.07 0.07
    Glycerin 3.0 3.0
    3.0 3.0
    NATRASOL 250 HR 0.5 0.5
    0.5 0.5
    KOH (45%) Up to the specified pH
    pH 3.0 2.0 4.0 5.0

    The active concentration in final solution is shown in bold.
  • [0085]
    Solution 32 was tested for its microbial activity using EN.12054 test method at 55% dilution against S.aureus, P.aeruginosa, E.hirae, and E.coli and showed more than 3 log reduction which is the criteria for a hand antiseptic. This solution was also tested against E.coli using EN.1499 and passed the test.
  • [0086]
    Solution 32 was also tested for its skin irritation using a patch test. In this study, the solution was put on patches and applied on the skin of 11 volunteers for 48 hours. No irritation was observed after the test, indicating that the solution is not a skin irritant.
  • [0087]
    Solution 32 was also tested for its hydrogen peroxide stability using a hot stability test method. The solution was kept at 70° C. for one week, which is equivalent to 1 year at room temperature. The loss for hydrogen peroxide was less than 5% proving remarkable stability of the solution.
  • [0088]
    The foregoing description is by way of example only and shall not be construed to limit the scope of the invention as defined by the following claims.

Claims (20)

  1. 1. An aqueous skin disinfecting solution having a pH of from about 2 to about 6 and comprising:
    (a) hydrogen peroxide in a concentration of from about 0.01 to about 4% w/w of the solution;
    (b) at least one surfactant chosen from imidazoline derivatives, alkyl betaines, alkyl amidopropyl betaine amides, alkyl amidopropyl betaines, alkylsulfo betaines, amine oxides and derivatives thereof in a concentration of from about 0.01 to about 15% w/w of the solution;
    (c) at least one hydrogen peroxide stabilizer in a concentration of from about 0.01 to about 4% w/w of the solution;
    (d) at least one member chosen from cyclic carboxylic acids and salts thereof in a concentration of from about 0.01 to about 4% w/w of the solution; and
    (e) at least one skin conditioning agent in a concentration of from about 0.01 to about 10% w/w of the solution.
  2. 2. The solution of claim 1, wherein the imidazoline derivatives are chosen from alkylamphocarboxylates and alkyliminocarboxylates.
  3. 3. The solution of claim 1, wherein the hydrogen peroxide stabilizer is chosen from phosphoric acid, phosphonic acids having 1 to 5 phosphonic acid groups, ethylenediaminetetraacetic acid (EDTA), diethylenetriaminepentaacetic acid (DTPA), N-(hydroxyethyl)-ethylenediaminetriacetic acid (HEDTA), nitrilotriacetic acid (NTA), 2-hydroxyethyliminodiacetic acid (HEIDA), benzoic acid, aminobenzoic acid, citric acid, iminodisuccinic acid, polyaspartic acid, and salts thereof.
  4. 4. The solution of claim 3, wherein the hydrogen peroxide stabilizer is chosen from sodium tripolyphosphate, 1-hydroxyethylidene-1,1,-diphosphonic acid, amino tri(methylene phosphonic acid), diethylenetriaminepenta(methylene phosphonic acid), 2-hydroxy ethylimino bis(methylene phosphonic acid), and ethylene diamine tetra(methylene phosphonic acid).
  5. 5. The solution of claim 1, wherein the carboxylic acid is chosen from furan carboxylic acid, benzoic acid and salicylic acid.
  6. 6. The solution of claim 5, comprising 2-furan carboxylic acid.
  7. 7. The solution of claim 1, wherein the skin conditioning agent is chosen from glycerides, sorbitol, castor oil, allantoin, cationic polymers, lanolin and its derivatives and cetyl alcohol.
  8. 8. The solution of claim 1, comprising at least one buffer in a concentration of from about 0.01 to about 5% w/w of the solution.
  9. 9. The solution of claim 8, wherein the buffer is chosen from citric acid, lactic acid, glycolic acid, phosphoric acid, malic acid, succinic acid and tartaric acid.
  10. 10. The solution of claim 1, comprising at least one hydrogen peroxide compatible surfactant in a concentration of from about 0.01 to about 10% w/w of the solution.
  11. 11. The solution of claim 1, comprising at least one C1 to C8 alcohol chosen from benzyl alcohol, ethanol, n-butanol, isopropanol, glycols in a concentration of from about 0.01 to about 10% w/w of solution.
  12. 12. The solution of claim 1, comprising at least one thickening agent compatible with hydrogen peroxide in a concentration of from about 0.01 to about 5% w/w of the solution.
  13. 13. The solution of claim 12, wherein the thickening agent is chosen from polyacrylic acid polymers, polysaccharides, and cellulose based polymers.
  14. 14. The solution of claim 1, comprising at least one member chosen from dyes and fragrances in a concentration of from about 0.001 to about 0.5% w/w of the solution.
  15. 15. The solution of claim 1, wherein the pH is from about 2.5 to about 5.
  16. 16. The solution of claim 1, wherein the hydrogen peroxide is present in a concentration of from about 0.25 to about 3% w/w of the solution.
  17. 17. The solution of claim 1, further comprising at least one member chosen from monocarboxylic acids, polycarboxylic acids, and mixtures thereof in a concentration of from about 0.01 to about 3% w/w of the solution.
  18. 18. An aqueous skin disinfecting solution having a pH of from about 2.5 to about 5 and comprising:
    (a) hydrogen peroxide in a concentration of from about 1 to about 3% w/w of the solution;
    (b) at least one surfactant chosen from alkyl betaines, alkyl amidopropyl betaines, alkyl amidopropyl betaine amides, alkylsulfo betaines, alkyl amphocarboxylates, alkyliminocarboxylates, amine oxides and derivatives thereof in a concentration of from about 1 to about 5% w/w of the solution;
    (c) at least one hydrogen peroxide stabilizer in a concentration of from about 0.01 to about 2% w/w of the solution;
    (d) at least one member chosen from cyclic carboxylic acids and salts thereof in a concentration of from about 0.05 to about 1 % w/w of the solution; and
    (e) at least one skin conditioning agent in a concentration of from about 0.5 to about 4% w/w of the solution.
  19. 19. A concentrated skin disinfectant solution, which can be diluted with water to form the solution of claim 1.
  20. 20. A dry powdered formulation, which can be dissolved in water to form the solution of claim 1.
US11128223 2004-05-14 2005-05-13 Hydrogen peroxide-based skin disinfectant Abandoned US20050255172A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US57080704 true 2004-05-14 2004-05-14
US11128223 US20050255172A1 (en) 2004-05-14 2005-05-13 Hydrogen peroxide-based skin disinfectant

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11128223 US20050255172A1 (en) 2004-05-14 2005-05-13 Hydrogen peroxide-based skin disinfectant
US13022683 US8808755B2 (en) 2004-05-14 2011-02-08 Hydrogen peroxide-based skin disinfectant
US13832921 US9198935B2 (en) 2004-05-14 2013-03-15 Hydrogen peroxide-based skin disinfectant

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13022683 Continuation US8808755B2 (en) 2004-05-14 2011-02-08 Hydrogen peroxide-based skin disinfectant

Publications (1)

Publication Number Publication Date
US20050255172A1 true true US20050255172A1 (en) 2005-11-17

Family

ID=35393899

Family Applications (3)

Application Number Title Priority Date Filing Date
US11128223 Abandoned US20050255172A1 (en) 2004-05-14 2005-05-13 Hydrogen peroxide-based skin disinfectant
US13022683 Active 2025-07-17 US8808755B2 (en) 2004-05-14 2011-02-08 Hydrogen peroxide-based skin disinfectant
US13832921 Active 2025-10-19 US9198935B2 (en) 2004-05-14 2013-03-15 Hydrogen peroxide-based skin disinfectant

Family Applications After (2)

Application Number Title Priority Date Filing Date
US13022683 Active 2025-07-17 US8808755B2 (en) 2004-05-14 2011-02-08 Hydrogen peroxide-based skin disinfectant
US13832921 Active 2025-10-19 US9198935B2 (en) 2004-05-14 2013-03-15 Hydrogen peroxide-based skin disinfectant

Country Status (4)

Country Link
US (3) US20050255172A1 (en)
EP (1) EP1765081A4 (en)
CA (1) CA2564763C (en)
WO (1) WO2005110090A1 (en)

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050058719A1 (en) * 2002-11-15 2005-03-17 Ramirez Jose A. Hydrogen peroxide disinfectant containing a cyclic carboxylic acid and/or aromatic alcohol
US20070059380A1 (en) * 2002-02-12 2007-03-15 Ramirez Jose A Enhanced activity hydrogen peroxide disinfectant
WO2007147815A1 (en) * 2006-06-23 2007-12-27 Henkel Ag & Co. Kgaa Dental treatment composition with increased bleaching effect
US20080305182A1 (en) * 2002-11-15 2008-12-11 Ramirez Jose A Hydrogen peroxide disinfectant containing a cyclic carboxylic acid and/or aromatic alcohol
US20090043010A1 (en) * 2005-10-28 2009-02-12 Mustafa Kaya Polymeric Compound, Method of Preparing a Polymeric Compound, Use of a Polymeric Compound
US20090041617A1 (en) * 2007-08-07 2009-02-12 Lee James D Purified hydrogen peroxide gas microbial control methods and devices
US20090247485A1 (en) * 2005-07-29 2009-10-01 Ahmed Fahim U Barrier film-forming compositions and methods of use
US20100130770A1 (en) * 2008-11-12 2010-05-27 Irix Pharmaceuticals N-alkanoyl-n,n',n'-alkylenediamine trialkanoic acid esters
WO2010077870A2 (en) * 2008-12-15 2010-07-08 Life Technologies Corporation Stable compositions comprising chromogenic compounds and methods of use
US20100204082A1 (en) * 2009-02-06 2010-08-12 Dober Chemical Corporation Alkaline compositions and methods of producing same
US20100265816A1 (en) * 2009-04-17 2010-10-21 American Superconductor Corporation Monitoring switching networks
US20110033557A1 (en) * 2008-04-04 2011-02-10 Giuseppe Augusto Scigliano Pharmaceutical composition and diagnostic and therapeutic use thereof
US20110182958A1 (en) * 2007-08-15 2011-07-28 Navid Omidbakhsh Antimicrobial compositions
US20120068113A1 (en) * 2009-01-26 2012-03-22 Innospec Limited Chelating agents and methods relating thereto
US20120193575A1 (en) * 2009-10-13 2012-08-02 Verutek, Inc. Stabilized surfactant - oxidant composition and related methods
WO2012125870A1 (en) * 2011-03-15 2012-09-20 Thompson Cooper Laboratories, Llc Compositions and methods for treatment of infections
WO2013096814A1 (en) * 2011-12-22 2013-06-27 Bui Huyen Phuong Non-corrosive stable peracetic acid concentrate solution
US20130259823A1 (en) * 2004-05-14 2013-10-03 Navid Omidbakhsh Hydrogen peroxide-based skin disinfectant
US20140079804A1 (en) * 2012-03-15 2014-03-20 Thompson Cooper Laboratories, Llc Compositions and methods for treatment of infections
WO2014121406A1 (en) * 2013-02-06 2014-08-14 Wetrok Ag Cleaning agent
USD744627S1 (en) 2014-07-23 2015-12-01 Lee Antimicrobial Solutions, Llc Air-permeable substrate structure
US9538760B2 (en) 2011-10-05 2017-01-10 Arkema Inc. Disinfectant compositions with hydrogen peroxide
EP3138401A1 (en) * 2015-09-04 2017-03-08 Weidner Chemie-Produktion GmbH Disinfectant composition
US9737076B2 (en) 2011-10-05 2017-08-22 Arkema Inc. Disinfectant compositions with hydrogen peroxide
US9789005B2 (en) 2009-09-02 2017-10-17 Hyprotek, Inc. Antimicrobial medical dressings and protecting wounds and catheter sites
USD814006S1 (en) 2014-07-18 2018-03-27 Synexis Llc Device for producing non-hydrated purified hydrogen peroxide gas

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007014575A1 (en) * 2005-08-02 2007-02-08 Thomas Besendorfer Composition having bactericidal, fungicidal, virucidal and insecticidal action
US9629361B2 (en) 2006-02-09 2017-04-25 Gojo Industries, Inc. Composition and method for pre-surgical skin disinfection
US20070185216A1 (en) * 2006-02-09 2007-08-09 Marcia Snyder Antiviral method
US8119115B2 (en) 2006-02-09 2012-02-21 Gojo Industries, Inc. Antiviral method
US8450378B2 (en) 2006-02-09 2013-05-28 Gojo Industries, Inc. Antiviral method
WO2008071746A1 (en) * 2006-12-13 2008-06-19 Centennial Ventures B.V. Mild composition for skin disinfection
EP2022331A1 (en) * 2007-08-02 2009-02-11 Wesso Ag Disinfectant for reducing the number of bacteria and biofilms
WO2010003431A1 (en) * 2008-07-07 2010-01-14 Paul Et Karin Herzog Sa Disinfecting composition
JP2017527599A (en) 2014-09-17 2017-09-21 ロンザ インコーポレーテッド Activated hydrogen peroxide disinfectant composition

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2528378A (en) * 1947-09-20 1950-10-31 John J Mccabe Jr Metal salts of substituted quaternary hydroxy cycloimidinic acid metal alcoholates and process for preparation of same
US4446153A (en) * 1982-09-30 1984-05-01 Ralston Purina Company Skin sanitizing composition and method of using
US5387605A (en) * 1992-07-31 1995-02-07 Eastman Kodak Company Carboxylic acids that are effective against TB
US5736582A (en) * 1996-10-10 1998-04-07 Devillez; Richard L. Method and composition for controlled delivery of nascent oxygen from hydrogen peroxide source for skin treatment
US6096348A (en) * 1996-02-12 2000-08-01 Healthpoint, Ltd. Quick acting chemical sterilant
US6444636B1 (en) * 2001-12-10 2002-09-03 Colgate-Palmolive Company Liquid dish cleaning compositions containing hydrogen peroxide
US6479454B1 (en) * 2000-10-05 2002-11-12 Ecolab Inc. Antimicrobial compositions and methods containing hydrogen peroxide and octyl amine oxide
US20020168422A1 (en) * 2000-04-28 2002-11-14 Hei Robert D.P. Two solvent antimicrobial compositions and methods employing them
US6617294B2 (en) * 2000-10-20 2003-09-09 Vinod K. Narula Waterless sanitizing hand cleanser
US6627589B1 (en) * 2001-05-11 2003-09-30 Colgate-Palmolive Company Mild antibacterial liquid dish cleaning compositions containing peroxide having improved stability and stain removal benefits
US6803057B2 (en) * 1998-12-14 2004-10-12 Virox Technologies Inc. Hydrogen peroxide disinfectant with increased activity
US6841090B1 (en) * 1998-04-08 2005-01-11 The Proctor & Gamble Company Disinfecting composition and process for disinfecting surfaces
US20050019421A1 (en) * 2003-07-23 2005-01-27 3M Innovative Properties Company Disinfecting compositions and methods of making and using same

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2629081C2 (en) 1976-06-29 1987-01-15 Peroxid-Chemie Gmbh, 8023 Hoellriegelskreuth, De
DE3229097C2 (en) 1982-08-04 1991-05-29 Schuelke & Mayr Gmbh, 2000 Hamburg, De
DE3543500C2 (en) 1985-12-10 1992-02-20 Schuelke & Mayr Gmbh, 2000 Norderstedt, De
DE3702983A1 (en) 1986-06-09 1987-12-10 Henkel Kgaa Disinfectants and their use for skin and mucous disinfection
EP0351772A3 (en) 1988-07-19 1990-07-04 HENKEL CORPORATION (a Delaware corp.) Stabilized hydrogen peroxide
DE4015202A1 (en) 1990-05-11 1991-11-14 Heimo Wessollek Cleaner for drinking water facilities
CA2061009C (en) 1991-03-25 1998-05-05 Mohammad Ali Khan Antimicrobial formulation
DE4225795C2 (en) 1992-07-31 1994-09-01 Schuelke & Mayr Gmbh Disinfectants carboxylic acid-based
WO1995004001A1 (en) 1993-07-28 1995-02-09 Heimo Wessollek Agent for reducing the germination index and stabilising drinking water and water for domestic uses
US5641530A (en) 1995-11-27 1997-06-24 Eka Nobel Inc. Method of disinfection
EP0839900A1 (en) 1996-10-31 1998-05-06 THE PROCTER & GAMBLE COMPANY Carpet cleaning compositions and method for cleaning carpets
US6114377A (en) 1997-07-17 2000-09-05 E-L Management Corp. Antimicrobial cosmetic compositions
EP1001012A1 (en) 1998-11-10 2000-05-17 THE PROCTER & GAMBLE COMPANY Disinfecting and cleaning compositions
EP1351658B1 (en) 2001-01-16 2005-03-02 Unilever N.V. Oral composition
US6555509B2 (en) * 2001-01-29 2003-04-29 Unilever Home & Personal Care Usa Division Of Conopco, Inc. Multi-phase toilet articles and methods for their manufacture
EP1374679A3 (en) 2002-06-21 2004-01-21 Nippon Peroxide Co., Ltd. Sterilizing composition and method for sterilizing using the same
US20030180377A1 (en) 2002-02-12 2003-09-25 Ramirez Jose A. Enhanced activity hydrogen peroxide disinfectant
CA2478595A1 (en) 2002-03-05 2003-09-18 Colgate-Palmolive Company Color stable liquid dish cleaning compositions containing a peroxide source
DE10224979B4 (en) 2002-06-05 2004-07-15 Schülke & Mayr GmbH Use of synergistic preparations based on mixtures of glycerol ethers with aromatic alcohol for controlling mycobacteria
CN100384971C (en) 2002-10-14 2008-04-30 阿科尼亚有限公司 Composition
CA2564763C (en) * 2004-05-14 2012-08-07 Virox Technologies Inc. Hydrogen peroxide-based skin disinfectant

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2528378A (en) * 1947-09-20 1950-10-31 John J Mccabe Jr Metal salts of substituted quaternary hydroxy cycloimidinic acid metal alcoholates and process for preparation of same
US4446153A (en) * 1982-09-30 1984-05-01 Ralston Purina Company Skin sanitizing composition and method of using
US5387605A (en) * 1992-07-31 1995-02-07 Eastman Kodak Company Carboxylic acids that are effective against TB
US6096348A (en) * 1996-02-12 2000-08-01 Healthpoint, Ltd. Quick acting chemical sterilant
US5736582A (en) * 1996-10-10 1998-04-07 Devillez; Richard L. Method and composition for controlled delivery of nascent oxygen from hydrogen peroxide source for skin treatment
US6841090B1 (en) * 1998-04-08 2005-01-11 The Proctor & Gamble Company Disinfecting composition and process for disinfecting surfaces
US6803057B2 (en) * 1998-12-14 2004-10-12 Virox Technologies Inc. Hydrogen peroxide disinfectant with increased activity
US20020168422A1 (en) * 2000-04-28 2002-11-14 Hei Robert D.P. Two solvent antimicrobial compositions and methods employing them
US6479454B1 (en) * 2000-10-05 2002-11-12 Ecolab Inc. Antimicrobial compositions and methods containing hydrogen peroxide and octyl amine oxide
US6617294B2 (en) * 2000-10-20 2003-09-09 Vinod K. Narula Waterless sanitizing hand cleanser
US6627589B1 (en) * 2001-05-11 2003-09-30 Colgate-Palmolive Company Mild antibacterial liquid dish cleaning compositions containing peroxide having improved stability and stain removal benefits
US6444636B1 (en) * 2001-12-10 2002-09-03 Colgate-Palmolive Company Liquid dish cleaning compositions containing hydrogen peroxide
US20050019421A1 (en) * 2003-07-23 2005-01-27 3M Innovative Properties Company Disinfecting compositions and methods of making and using same

Cited By (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070059380A1 (en) * 2002-02-12 2007-03-15 Ramirez Jose A Enhanced activity hydrogen peroxide disinfectant
US7632523B2 (en) 2002-02-12 2009-12-15 Virox Technologies Inc. Enhanced activity hydrogen peroxide disinfectant
US20100003343A1 (en) * 2002-02-12 2010-01-07 Ramirez Jose A Enhanced activity hydrogen peroxide disinfectant
US8999400B2 (en) 2002-02-12 2015-04-07 Virox Technologies Inc. Enhanced activity hydrogen peroxide disinfectant
US8637085B2 (en) 2002-02-12 2014-01-28 Virox Technologies Inc. Enhanced activity hydrogen peroxide disinfectant
US20100330196A1 (en) * 2002-02-12 2010-12-30 Ramirez Jose A Enhanced activity hydrogen peroxide disinfectant
US9233180B2 (en) 2002-11-15 2016-01-12 Virox Technologies Inc. Hydrogen peroxide disinfectant containing a cyclic carboxylic acid and/or aromatic alcohol
US20050058719A1 (en) * 2002-11-15 2005-03-17 Ramirez Jose A. Hydrogen peroxide disinfectant containing a cyclic carboxylic acid and/or aromatic alcohol
US7354604B2 (en) 2002-11-15 2008-04-08 Virox Technologies Inc. Hydrogen peroxide disinfectant containing a cyclic carboxylic acid and/or aromatic alcohol
US20080305182A1 (en) * 2002-11-15 2008-12-11 Ramirez Jose A Hydrogen peroxide disinfectant containing a cyclic carboxylic acid and/or aromatic alcohol
US20130259823A1 (en) * 2004-05-14 2013-10-03 Navid Omidbakhsh Hydrogen peroxide-based skin disinfectant
US9198935B2 (en) * 2004-05-14 2015-12-01 Virox Technologies Inc. Hydrogen peroxide-based skin disinfectant
US8778369B2 (en) 2005-07-29 2014-07-15 Delaval Holding Ab Barrier film-forming compositions and methods of use
US20090247485A1 (en) * 2005-07-29 2009-10-01 Ahmed Fahim U Barrier film-forming compositions and methods of use
US8664295B2 (en) * 2005-10-28 2014-03-04 Nutripol Capital Sarl Polymeric compound, method of preparing a polymeric compound, use of a polymeric compound
US20090043010A1 (en) * 2005-10-28 2009-02-12 Mustafa Kaya Polymeric Compound, Method of Preparing a Polymeric Compound, Use of a Polymeric Compound
WO2007147815A1 (en) * 2006-06-23 2007-12-27 Henkel Ag & Co. Kgaa Dental treatment composition with increased bleaching effect
US8685329B2 (en) 2007-08-07 2014-04-01 Lee Antimicrobial Solutions Llc Purified hydrogen peroxide gas microbial control methods and devices
US9370592B2 (en) 2007-08-07 2016-06-21 Lee Antimicrobial Solutions Llc Purified hydrogen peroxide gas microbial control methods and devices
US20090041617A1 (en) * 2007-08-07 2009-02-12 Lee James D Purified hydrogen peroxide gas microbial control methods and devices
US8168122B2 (en) 2007-08-07 2012-05-01 Lee Antimicrobial Solutions Llc Purified hydrogen peroxide gas microbial control methods and devices
US9034255B2 (en) 2007-08-07 2015-05-19 Lee Antimicrobial Solutions Llc Purified hydrogen peroxide gas microbial control methods and devices
US20110182958A1 (en) * 2007-08-15 2011-07-28 Navid Omidbakhsh Antimicrobial compositions
US8865196B2 (en) 2007-08-15 2014-10-21 Virox Technologies Inc. Antimicrobial compositions
US20110033557A1 (en) * 2008-04-04 2011-02-10 Giuseppe Augusto Scigliano Pharmaceutical composition and diagnostic and therapeutic use thereof
US20100130770A1 (en) * 2008-11-12 2010-05-27 Irix Pharmaceuticals N-alkanoyl-n,n',n'-alkylenediamine trialkanoic acid esters
US8258334B2 (en) 2008-11-12 2012-09-04 Irix Pharmaceuticals, Inc. N-alkanoyl-N,N′,N′-alkylenediamine trialkanoic acid esters
WO2010077870A2 (en) * 2008-12-15 2010-07-08 Life Technologies Corporation Stable compositions comprising chromogenic compounds and methods of use
WO2010077870A3 (en) * 2008-12-15 2010-10-28 Life Technologies Corporation Stable compositions comprising chromogenic compounds and methods of use
US8801962B2 (en) * 2009-01-26 2014-08-12 Innospec Limited Chelating agents and methods relating thereto
US20120068113A1 (en) * 2009-01-26 2012-03-22 Innospec Limited Chelating agents and methods relating thereto
US20100204082A1 (en) * 2009-02-06 2010-08-12 Dober Chemical Corporation Alkaline compositions and methods of producing same
US8293696B2 (en) * 2009-02-06 2012-10-23 Ecolab, Inc. Alkaline composition comprising a chelant mixture, including HEIDA, and method of producing same
US20100265816A1 (en) * 2009-04-17 2010-10-21 American Superconductor Corporation Monitoring switching networks
US9789005B2 (en) 2009-09-02 2017-10-17 Hyprotek, Inc. Antimicrobial medical dressings and protecting wounds and catheter sites
US20120193575A1 (en) * 2009-10-13 2012-08-02 Verutek, Inc. Stabilized surfactant - oxidant composition and related methods
EP2685820A1 (en) * 2011-03-15 2014-01-22 Thompson Cooper Laboratories, LLC Compositions and methods for treatment of infections
US20140044658A1 (en) * 2011-03-15 2014-02-13 Thompson Cooper Laboratories, Llc Compositions and Methods for Treatment of Infections
WO2012125870A1 (en) * 2011-03-15 2012-09-20 Thompson Cooper Laboratories, Llc Compositions and methods for treatment of infections
EP2685820A4 (en) * 2011-03-15 2014-08-27 Thompson Cooper Lab Llc Compositions and methods for treatment of infections
US9538760B2 (en) 2011-10-05 2017-01-10 Arkema Inc. Disinfectant compositions with hydrogen peroxide
US9737076B2 (en) 2011-10-05 2017-08-22 Arkema Inc. Disinfectant compositions with hydrogen peroxide
WO2013096814A1 (en) * 2011-12-22 2013-06-27 Bui Huyen Phuong Non-corrosive stable peracetic acid concentrate solution
US20140079804A1 (en) * 2012-03-15 2014-03-20 Thompson Cooper Laboratories, Llc Compositions and methods for treatment of infections
WO2014121406A1 (en) * 2013-02-06 2014-08-14 Wetrok Ag Cleaning agent
USD814006S1 (en) 2014-07-18 2018-03-27 Synexis Llc Device for producing non-hydrated purified hydrogen peroxide gas
USD744627S1 (en) 2014-07-23 2015-12-01 Lee Antimicrobial Solutions, Llc Air-permeable substrate structure
EP3138401A1 (en) * 2015-09-04 2017-03-08 Weidner Chemie-Produktion GmbH Disinfectant composition

Also Published As

Publication number Publication date Type
CA2564763A1 (en) 2005-11-24 application
EP1765081A1 (en) 2007-03-28 application
US8808755B2 (en) 2014-08-19 grant
EP1765081A4 (en) 2012-07-04 application
CA2564763C (en) 2012-08-07 grant
US9198935B2 (en) 2015-12-01 grant
WO2005110090A1 (en) 2005-11-24 application
US20130259823A1 (en) 2013-10-03 application
US20110129435A1 (en) 2011-06-02 application

Similar Documents

Publication Publication Date Title
US4919837A (en) Antiseptic cleansing composition comprising a water-soluble salt of chlorhexidine
US5942478A (en) Microbicidal and sanitizing soap compositions
US4597975A (en) Iodine surface active compositions
US5547990A (en) Disinfectants and sanitizers with reduced eye irritation potential
US6296880B1 (en) Pharmaceutical compositions and methods for managing skin conditions
US5244666A (en) Presurgical skin scrub and disinfectant
US6617294B2 (en) Waterless sanitizing hand cleanser
US6090772A (en) Triclosan skin wash with enhanced efficacy
US5308611A (en) Antiseptic composition
US6488942B1 (en) Disinfecting agent
US5266598A (en) Skin disinfectant compositions
US20060263323A1 (en) Invisible antimicrobial glove and hand antiseptic
US4975217A (en) Virucidal composition, the method of use and the product therefor
US20050048005A1 (en) Antimicrobial compositions for dental applications
US6358906B1 (en) Concentrated liquid accumulations comprising a microbicidally active ingredient
US5229103A (en) Antiplaque mouthwash concentrate
US6413921B1 (en) Antimicrobial composition containing parachlorometaxylenol (PCMX)
US20030180377A1 (en) Enhanced activity hydrogen peroxide disinfectant
JPH08151324A (en) Antimicrobial preparation
US6139859A (en) Methods and compositions for topical treatment of ectoparasites
US20120129950A1 (en) Antimicrobial compositions
US20090035339A1 (en) Methods of Inactivating Viruses
US7338927B2 (en) Wide spectrum disinfectant comprising an alcohol and disinfectant mixture
CN101684435A (en) Sterilization hand washing solution
US20060074029A1 (en) Topical antimicrobial composition having improved moisturization properties

Legal Events

Date Code Title Description
AS Assignment

Owner name: VIROX TECHNOLOGIES INC., CANADA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:OMIDBAKHSH, NAVID;REEL/FRAME:016119/0234

Effective date: 20050511

AS Assignment

Owner name: VIROX TECHNOLOGIES INC., CANADA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:GRASCHA, PIERRE;REEL/FRAME:019414/0912

Effective date: 20061024